Search

Displaying results 6351 - 6360 of 8171 in total
  1. Drug

    Izuforant

    go.drugbank.com/drugs/DB21571
    Experimental

    Izuforant has a monoisotopic molecular weight of 333.03 Da.

  2. Drug

    Inixaciclib

    go.drugbank.com/drugs/DB21584
    Experimental

    Inixaciclib has a monoisotopic molecular weight of 480.24 Da.

  3. Drug

    Culmerciclib

    go.drugbank.com/drugs/DB21600
    Investigational

    Culmerciclib has a monoisotopic molecular weight of 446.23 Da.

  4. Drug

    Monzosertib

    go.drugbank.com/drugs/DB21619
    Investigational

    Monzosertib has a monoisotopic molecular weight of 465.16 Da.

  5. Drug

    Votoplam

    go.drugbank.com/drugs/DB21645
    Investigational

    Votoplam has a monoisotopic molecular weight of 419.22 Da.

  6. Drug

    Potrasertib

    go.drugbank.com/drugs/DB21682
    Experimental

    Potrasertib has a monoisotopic molecular weight of 564.19 Da.

  7. Drug

    Tigemocoxib

    go.drugbank.com/drugs/DB21699
    Experimental

    Tigemocoxib has a monoisotopic molecular weight of 334.06 Da.

  8. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSynonyms: (2,3-Dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate
  9. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

  10. Drug

    EMZ702

    go.drugbank.com/drugs/DB05021
    Investigational

    EMZ702, a non-toxic agent that has strong anti-viral synergy with interferon, is an ideal candidate for combination with current standard hepatitis C treatments. … EMZ702 has an excellent safety profile and the combination of EMZ702 with interferon and ribavirin in surrogate models for hepatitis C has demonstrated a two to three fold increase in anti-viral potency